Skip to main content
. 2022 May 26;2022(5):CD013506. doi: 10.1002/14651858.CD013506.pub2

IRCT2016012420024N3 2016.

Study name Nebulised magnesium sulfate treatment in acute exacerbation of chronic obstructive pulmonary disease
Methods Study design: phase 2 to 3 randomised double‐blind placebo‐controlled trial of parallel assignment
Participants Inclusion criteria

  1. known history of chronic obstructive pulmonary disease (COPD) based on previous clinical history and spirometry;

  2. presenting to emergency department with at least two of following symptoms: shortness of breath, increase in the amount of sputum/purulent pattern of the sputum;

  3. age > 40 years;

  4. within 24 h of hospital admission;

  5. smoking history > 20 pack‐years;


Exclusion criteria

  1. patient with unstable vital signs;

  2. intubated patient;

  3. associated comorbidity (pneumothorax, pulmonary embolism, pneumonia, acute coronary syndrome, congestive heart failure, neuromuscular disease, active malignancy and etc.);

  4. unconscious patient;

  5. inability to perform spirometry;

  6. nursing/pregnant women;

  7. previous history of allergy to magnesium sulfate;


Age minimum: 40 years
Age maximum: no limit
Gender: both
Interventions Intervention: 2.5 mLmagnesium sulfate Vial 20% by nebulizer mask
Placebo: 2.5 mLsodium chloride 0.9%
Outcomes Primary outcomes

  • Lung volumes

  • Arterial oxygen saturation of haemoglobin

  • COPD Assessment Test (CAT) questionnaire, Persian version


Secondary outcomes

  • Duration of hospitalisation
Starting date 22 January 2016
Contact information Dr. Besharat Rahimi
Advanced Thoracic Research Cente, Imamkhomeini medical complex, Keshavarz blvd.Tehran Iran (Islamic Republic of)
besharatrahimi@yahoo.com
Notes Sponsor: Vice chancellor for research, Tehran University of Medical Sciences